Envonalkib |
Katalog-Nr.GC65380 |
Envonalkib ist ein potenter und oral aktiver Inhibitor von ALK mit IC50-Werten von 1,96 nM, 35,1 nM und 61,3 nM fÜr WT und mutiertes L1196M und G1269S-ALK. Envonalkib kann zur Erforschung von nicht-kleinzelligem Lungenkrebs eingesetzt werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1621519-26-3
Sample solution is provided at 25 µL, 10mM.
Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer[1].
Envonalkib (formula I) (12.5-25 mg/kg; p.o. once daily for 14 days) inhibits the growth of human non-small cell lung cancer NCI-H2228 nude mice xenografts[1].
[1]. Feng G, et, al. Pyridine-substituted 2-aminopyridine protein kinase inhibitors. WO2016015676A1.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *